CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. (CERO)
Overview
CERo Therapeutics Holdings, Inc. is a South San Francisco, California-based clinical-stage immunotherapy company developing engineered T-cell therapies for cancer, most recently through a business combination that took the private CERo Therapeutics public. As of the September 2026 reporting window the company's securities have been delisted from Nasdaq and trade over-the-counter under CERO (with associated warrants trading as CEROW), and its market capitalization has fallen to under $1 million, down roughly 88% year over year. The company's fiscal 2025 10-K explicitly states "substantial doubt as to our ability to continue as a going concern," reflecting the capital-intensive, pre-revenue nature of clinical-stage biotech combined with acute balance-sheet stress. CERo remains a real, SEC-reporting operating company — its lead program is in an active Phase 1 clinical trial — but it is a highly speculative, early-stage story rather than a commercially established business.
What They Do & How They Make Money
CERo has no approved products and generates no meaningful commercial revenue; its business is the research, clinical development, and eventual licensing or commercialization of its proprietary "Chimeric Engulfment Receptor T cell" (CER-T) platform, which combines the phagocytic (engulfment) mechanisms of the innate immune system with the cytotoxic killing mechanisms of adaptive T cells in a single engineered construct. Its lead candidate, CER-1236, targets TIM-4 ligand-expressing tumor cells (via phosphatidylserine recognition) and is designed using manufacturing and lentiviral-delivery processes that parallel existing, FDA-approved CAR-T production methods, intended to shorten development and regulatory timelines. The company's near-term "revenue" model, typical of clinical-stage biotech, is entirely dependent on raising external capital — PIPE financings, common stock and preferred stock offerings, warrant issuances, and an equity line of credit commitment of up to $25 million from Keystone Capital Partners — to fund trials toward an eventual product approval, partnership, or acquisition.
Pipeline & Clinical Status
CER-1236's Phase 1 dose-escalation trial in relapsed/refractory acute myeloid leukemia (AML) began in May 2025; as of the April 2026 10-K, five patients had been dosed, with the first four clearing 28-day safety monitoring without dose-limiting toxicities and showing measurable T-cell expansion. The AML protocol was subsequently amended to include myelodysplastic syndrome and myelofibrosis patients based on early safety signals. A second FDA-accepted IND covering non-small cell lung cancer and ovarian cancer was cleared in March 2025, with a Phase 1 start targeted for Q1 2026. The FDA granted CER-1236 Orphan Drug Designation (July 2025) and Fast Track Designation (September 2025) for AML.
Competitors
- Approved CAR-T therapy makers (seven FDA-approved CAR-T products exist for hematologic cancers) — none currently approved specifically for AML, which CERo is targeting as a differentiated entry point.
- Other clinical-stage cell-therapy developers pursuing solid-tumor and AML-focused engineered T-cell or NK-cell approaches.
- Large pharmaceutical and biotech oncology franchises with far greater capital, manufacturing, and commercial infrastructure that could out-develop or acquire competing approaches.
Competitive Position
CERo's technology differentiation — combining phagocytic and cytotoxic killing mechanisms in one construct — is scientifically novel and targets a real unmet need (no FDA-approved CAR-T product exists for AML today), and its early Phase 1 safety data and regulatory designations (Orphan Drug, Fast Track) are genuine, if preliminary, positives. However, the company's competitive position is extremely fragile: it has no revenue, an explicit going-concern warning, a market capitalization under $1 million, and a Nasdaq delisting that has pushed the stock to thin, illiquid OTC trading. Its path forward depends entirely on continuing to fund a lengthy, expensive, and high-attrition clinical development process (most oncology candidates fail in Phase 1/2) while competing for capital, patients, and talent against far better-funded cell-therapy developers. Any moat CERo has today is purely in its early-stage intellectual property and clinical data, not in any commercial, financial, or scale advantage.